Eikon Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Eikon Therapeutics ended Q2 2026 with $531.2M in cash (62% of total assets ~$850.8M), enabling operations into H2 2027. The company reported Q2 net loss of $88.4M (vs. $105.2M prior year) with R&D expenses of $75.5M (up 9% YoY) and G&A of $17.9M (down 56% YoY, reflecting prior-year impairment charges). Seven abstracts on oncology pipeline (EIK1001, EIK1003, EIK1004, EIK1005) accepted for ESMO October 2026; TeLuRide-006 Phase 2/3 melanoma trial passed interim analysis; TeLuRide-008 NSCLC trial dosing initiated; Ma. Fatima Francisco appointed to Board.
Why this rating
Clinical progress and ESMO presentations are encouraging; cash runway extended but burn rate remains high. Meaningful but not transformational for stage of company.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.